GNVC Profile
GenVec, Inc. (GNVC) is a clinical-stage biotechnology company that focuses on developing therapies and vaccines for patients suffering from infectious diseases and cancer. The company's proprietary AdenoVerse technology platform allows it to design and produce novel gene-based therapeutics.
GenVec's lead product candidate is CGF166, a gene therapy being developed for the treatment of hearing loss and balance disorders. The therapy is currently being evaluated in a Phase 1/2 clinical trial. The company is also working on the development of a vaccine for the prevention of respiratory syncytial virus (RSV), which is currently in preclinical testing.
In addition to its proprietary programs, GenVec has also collaborated with other companies and organizations to advance the development of new therapies and vaccines. For example, the company has partnered with Novartis to develop treatments for hearing loss, and has worked with the U.S. Department of Defense to develop a vaccine for the prevention of malaria.
GenVec was founded in 1992 and is headquartered in Gaithersburg, Maryland.
|
